2 news items
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease
COYA
22 May 24
an estimated 5.7 million Americans. In more than 90% of people with Alzheimer's, symptoms do not appear until after age 60. The incidence of the disease
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)
COYA
20 May 24
million Americans. In more than 90% of people with Alzheimer's, symptoms do not appear until after age 60. The incidence of the disease increases
- Prev
- 1
- Next